Both tissue and plasma groups showed significant association between FHIT methylation and NSCLC (OR = 3.68 and 3.89, respectively) (Figure 3D), which suggested that FHIT methylation test is a promising biomarker for NSCLC diagnosis with either tissue or plasma samples. This evidence concerns the gene FHIT and non-small cell lung carcinoma.